Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Guadecitabine in AML
NCT02892318Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in acute myeloid leukemia (AML) (4 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events at 32 months, Percentage of Participants with Complete Remission (CR) at 24 weeks and 3 more. Started Oct 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02892318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892318.